Cargando…

Do the benefits of being a smoker hint at the existence of PD-1/PD-L1 sensitizers for patients on single-agent immunotherapy?

Multiple studies demonstrate significantly better therapeutics outcomes in smokers as compared with never smokers when single-agent immunotherapy is applied. Non-smoker patients usually need a combination of chemoimmunotherapy to achieve comparable or slightly better therapeutic results. This effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaleskis, Gintaras, Pasukoniene, Vita, Characiejus, Dainius, Urbonas, Vincas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Hypothesis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8378371/ https://www.ncbi.nlm.nih.gov/pubmed/34413168 http://dx.doi.org/10.1136/jitc-2021-003191

Ejemplares similares

Doxorubicin uptake in ascitic lymphoma model: resistance or curability is governed by tumor cell density and prolonged drug retention
por: Zaleskis, Gintaras, et al.
Publicado: (2020)

Letter to the Editor Re: Yamamoto R, Sugiura T, Ashida R, Ohgi K, Yamada M, Otsuka S, and Uesaka K. Prognostic value of carbohydrate antigen 19‐9 and the surgical margin in extrahepatic cholangiocarcinoma. Ann Gastroenterol Surg. 2022; 6:307–315
por: Zaleskis, Gintaras, et al.
Publicado: (2023)

Letter to the Editor: No immunophenotyping in peripheral blood of prostate cancer patients treated with neoadjuvant Rituximab?
por: Bosas, Paulius, et al.
Publicado: (2020)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample
por: Eidukevicius, Rimantas, et al.
Publicado: (2005)

Correction: a method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample
por: Eidukevicius, Rimantas, et al.
Publicado: (2006)

Analysis of G6PD enzyme deficiency in Saudi population
por: Alharbi, Khalid K, et al.
Publicado: (2012)

Hypothetical COVID-19 protection mechanism: hints from centenarians
por: Guerini, Franca Rosa, et al.
Publicado: (2021)

Thrombophilic gene polymorphism studies in G6PD deficient individuals from Saudi population
por: Alharbi, Khalid K, et al.
Publicado: (2012)

Immunophenotype Rearrangement in Response to Tumor Excision May Be Related to the Risk of Biochemical Recurrence in Prostate Cancer Patients
por: Bosas, Paulius, et al.
Publicado: (2021)

Insertion/Deletion polymorphisms do play any role in G6PD deficiency individuals in the Kingdom of the Saudi Arabia
por: Alharbi, Khalid K, et al.
Publicado: (2013)

The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy
por: Qian, Jiawen, et al.
Publicado: (2018)

Modifiable risk factors of lung cancer in “never-smoker” women
por: Bae, Jong-Myon
Publicado: (2015)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

Melatonin and Hippo Pathway: Is There Existing Cross-Talk?
por: Lo Sardo, Federica, et al.
Publicado: (2017)

Targeting PD-1/PD-L1 interactions for cancer immunotherapy
por: Zitvogel, Laurence, et al.
Publicado: (2012)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

Simultaneous dual targeting of Par-4 and G6PD: a promising new approach in cancer therapy? Quintessence of a literature review on survival requirements of tumor cells
por: Cernaj, Ingeborg Elisabeth
Publicado: (2016)

Why Do Some Reports Claim that the Number of COVID-19 Hospitalized Smokers is Smaller than Expected?
por: J. J., Bevelacqua, et al.
Publicado: (2020)

Dysregulated ferroptosis‐related genes indicate potential clinical benefits for anti–PD‐1/PD‐L1 immunotherapy in lung adenocarcinoma
por: Zhou, Min, et al.
Publicado: (2021)

Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
por: Chardin, Laure, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy
por: Bevins, Nicholas J., et al.
Publicado: (2022)

Rethinking the immunotherapy numbers game
por: Bekker, Rebecca A, et al.
Publicado: (2022)

Highlight report: Role of PD-L1 in never-smokers
por: Albrecht, Wiebke
Publicado: (2019)

An in silico analytical study of lung cancer and smokers datasets from gene expression omnibus (GEO) for prediction of differentially expressed genes
por: Hasan, Atif Noorul, et al.
Publicado: (2015)

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
por: Villanueva, Nicolas, et al.
Publicado: (2018)

Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
por: Wang, Xin, et al.
Publicado: (2019)

Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
por: Zhang, Min, et al.
Publicado: (2019)

PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
por: Li, Qian, et al.
Publicado: (2022)

Systemic CD4 Immunity and PD-L1/PD-1 Blockade Immunotherapy
por: Escors, David, et al.
Publicado: (2022)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

PD-1/PD-L1 inhibitors as a hope for smokers of non-small cell lung cancer patient
por: Yu, Zhuo, et al.
Publicado: (2019)

Model Communities Hint at Promiscuous Metabolic Linkages between Ubiquitous Free-Living Freshwater Bacteria
por: Garcia, Sarahi L., et al.
Publicado: (2018)

Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022)

Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy
por: Liu, Bingshan, et al.
Publicado: (2017)

Enhancement of PSMA-Directed CAR Adoptive Immunotherapy by PD-1/PD-L1 Blockade
por: Serganova, Inna, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l9jd0eho4p41ku495s34vjk2h8